Plain-English translation of NCT06992739 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether trilaciclib, a medication designed to protect bone marrow, can help patients with advanced lung cancer better tolerate a newer cancer-fighting drug called sacituzumab tirumotecan. You would receive trilaciclib before and alongside the new treatment. The goal is to reduce severe side effects that affect your blood cells while improving how well the medication works against your cancer.
Some patients with lung cancer develop resistance to standard treatments and need new options, but those new options can cause serious drops in blood cell counts. This medication aims to protect your bone marrow so your body can better handle the stronger cancer-fighting treatment.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly to receive trilaciclib as an infusion before each dose of the cancer-fighting medication. The study lasts until your cancer gets worse, you cannot tolerate the side effects, or you choose to stop. Throughout the trial, you'll have frequent blood tests to monitor your cell counts, imaging scans every 6 weeks to check how your cancer is responding, and regular check-ins with your care team.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China